- Titel
- Successful Combination of Olaparib and ²²⁵Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-957246
- Quellenangabe
- Case reports in oncology
Erscheinungsjahr: 2023
Jahrgang: 16
Heft: 1
Seiten: 1166-1171
E-ISSN: 1662-6575 - Erstveröffentlichung
- 2023
- Abstract (EN)
- Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (¹⁷⁷Lu) – DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and grade 2 (G2) of the intestine. After the failure of ¹⁷⁷Lu-DOTATATE therapy, targeted alpha-particle therapy (TAT) may be a possible treatment option. Here, we present a patient with cancer of unknown primary NET G2 later G3. The patient was referred to our hospital with urosepsis due to a second-degree urinary retention. After stent insertion, a contrast-enhanced computed tomography revealed a huge pelvic tumor without metastases. Initially, the patient had undergone surgical treatment. Later the patient developed liver metastasis and was treated by ¹⁷⁷Lu-DOTATATE therapy and four lines of systemic therapy. A disease progression was observed and with the knowledge of a germline BRCA1 mutation, the patient was treated with TAT (Actinium-225 [²²⁵Ac]-DOTATATE) combined with olaparib. The patient achieved a significant treatment response for 12 months indicating that a combination therapy with an alpha emitter and olaparib demands further investigations in clinical trials.
- Andere Ausgabe
- Link zum Artikel, der zuerst in der Zeitschrift „Case reports in oncology” im Verlag Karger erschienen ist.
DOI: 10.1159/000533198 - Freie Schlagwörter (EN)
- Neuroendocrine tumor, Peptide receptor radionuclide therapy, BRCA mutation, Olaparib, Targeted alpha-particle therapy
- Klassifikation (DDC)
- 610
- Verlag
- Karger, Basel
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-957246
- Veröffentlichungsdatum Qucosa
- 04.11.2025
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY-NC 4.0